Damora Therapeutics, Inc. Common Stock’s (DMRA) Buy Rating Reaffirmed at HC Wainwright

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $45.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 36.40% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Wedbush reaffirmed an “outperform” rating and issued a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price on the stock. TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They set a “buy” rating for the company. Finally, Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Up 4.8%

Shares of DMRA opened at $32.99 on Tuesday. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The stock has a market capitalization of $2.03 billion, a P/E ratio of -5.91 and a beta of 1.46. The company has a 50 day moving average of $25.05 and a 200-day moving average of $25.58.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DMRA. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth about $6,574,000. Jain Global LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $2,774,000. Remedium Capital Partners LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,204,000. Finally, Connective Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth approximately $100,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.